Hardman Johnston Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.1M | Sell |
58,357
-5,449
| -9% | -$2.54M | 1.24% | 20 |
|
|
2025
Q4 | $28.9M | Sell |
63,806
-15,346
| -19% | -$6.61M | 1.38% | 21 |
|
|
2025
Q3 | $31M | Sell |
79,152
-29,073
| -27% | -$12.2M | 1.52% | 20 |
|
|
2025
Q2 | $48.2M | Sell |
108,225
-9,855
| -8% | -$4.54M | 2.14% | 15 |
|
|
2025
Q1 | $57.2M | Buy |
118,080
+3,416
| +3% | +$1.59M | 2.73% | 12 |
|
|
2024
Q4 | $46.2M | Sell |
114,664
-245
| -0.2% | -$114K | 1.91% | 16 |
|
|
2024
Q3 | $53.4M | Sell |
114,909
-6,911
| -6% | -$3.32M | 2.09% | 16 |
|
|
2024
Q2 | $57.1M | Sell |
121,820
-36,961
| -23% | -$16M | 2.21% | 15 |
|
|
2024
Q1 | $66.4M | Sell |
158,781
-14,180
| -8% | -$5.99M | 2.29% | 16 |
|
|
2023
Q4 | $70.4M | Sell |
172,961
-2,882
| -2% | -$1.06M | 2.26% | 17 |
|
|
2023
Q3 | $61.1M | Sell |
175,843
-1,617
| -0.9% | -$566K | 2.05% | 16 |
|
|
2023
Q2 | $62.4M | Sell |
177,460
-9,864
| -5% | -$3.32M | 2.02% | 17 |
|
|
2023
Q1 | $59M | Sell |
187,324
-19,403
| -9% | -$5.82M | 1.93% | 16 |
|
|
2022
Q4 | $59.7M | Sell |
206,727
-7,273
| -3% | -$2.22M | 2.34% | 11 |
|
|
2022
Q3 | $62M | Sell |
214,000
-17,914
| -8% | -$5.15M | 2.79% | 7 |
|
|
2022
Q2 | $65.4M | Sell |
231,914
-13,090
| -5% | -$3.5M | 2.77% | 9 |
|
|
2022
Q1 | $63.9M | Buy |
245,004
+36,380
| +17% | +$8.63M | 2.05% | 17 |
|
|
2021
Q4 | $45.8M | Buy |
208,624
+19,950
| +11% | +$3.88M | 1.24% | 23 |
|
|
2021
Q3 | $34.2M | Sell |
188,674
-3,505
| -2% | -$684K | 0.92% | 27 |
|
|
2021
Q2 | $38.7M | Sell |
192,179
-4,015
| -2% | -$840K | 0.94% | 24 |
|
|
2021
Q1 | $42.2M | Buy |
196,194
+500
| +0.3% | +$110K | 1.2% | 18 |
|
|
2020
Q4 | $46.3M | Sell |
195,694
-985
| -0.5% | -$226K | 1.34% | 17 |
|
|
2020
Q3 | $53.5M | Sell |
196,679
-2,515
| -1% | -$694K | 2% | 12 |
|
|
2020
Q2 | $57.8M | Sell |
199,194
-18,960
| -9% | -$5.14M | 2.55% | 10 |
|
|
2020
Q1 | $51.9M | Sell |
218,154
-1,050
| -0.5% | -$241K | 3.02% | 8 |
|
|
2019
Q4 | $48M | Sell |
219,204
-8,056
| -4% | -$1.63M | 1.94% | 15 |
|
|
2019
Q3 | $38.5M | Sell |
227,260
-1,790
| -0.8% | -$317K | 1.76% | 16 |
|
|
2019
Q2 | $42M | Sell |
229,050
-9,520
| -4% | -$1.66M | 1.86% | 15 |
|
|
2019
Q1 | $43.9M | Sell |
238,570
-4,015
| -2% | -$742K | 1.93% | 15 |
|
|
2018
Q4 | $40.2M | Sell |
242,585
-9,635
| -4% | -$1.67M | 2.08% | 15 |
|
|
2018
Q3 | $48.6M | Sell |
252,220
-3,930
| -2% | -$700K | 2.1% | 13 |
|
|
2018
Q2 | $43.5M | Buy |
256,150
+67,250
| +36% | +$10.4M | 1.84% | 12 |
|
|
2018
Q1 | $30.8M | Buy |
+188,900
| New | +$30.9M | 1.31% | 20 |
|
Other funds holding VRTX
VCM
VPM
Hardman Johnston Global Advisors's VRTX Position: Q1 2026 in Review
Hardman Johnston Global Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 8.5% in Q1 2026, selling an estimated $2.54M and leaving 58,357 shares worth $26.1M. The position accounts for 1.24% of the portfolio, ranked #20.
Hardman Johnston Global Advisors first reported a position in VRTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $70.4M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Hardman Johnston Global Advisors held 58,357 shares of Vertex Pharmaceuticals worth $26.1M as of Q1 2026.
- Hardman Johnston Global Advisors sold 5,449 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.54M.
- Vertex Pharmaceuticals made up 1.24% of Hardman Johnston Global Advisors's portfolio in Q1 2026, its #20 holding.
- Hardman Johnston Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
- Hardman Johnston Global Advisors's Vertex Pharmaceuticals position peaked at $70.4M in Q4 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Hardman Johnston Global Advisors's 13F filing for Q1 2026, filed 13 May 2026.